Withdrawal of rofecoxib (Vioxx®): What about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?;Retrait du rofecoxib (Vioxx®): À propos de la sécurité cardiovasculaire des anti-inflammatoires non stéroïdiens COX-2 sélectifs

Revue Medicale de Liege

Volumn 59, Issue 10, 2004, Pages 565-569

  Scheen, A J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

Acute myocardial infarction; Celecoxib; COX 2; Drug adverse event; NSAID; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTACYCLIN; ROFECOXIB; VALDECOXIB; ISOENZYME; LACTONE; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; SULFONE;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DRUG ADMINISTRATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG UTILIZATION; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; OSTEOARTHRITIS; POLYARTHRITIS; REVIEW; RHEUMATIC FEVER; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; POSTMARKETING SURVEILLANCE;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES;

EID: 9644289351     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Malaise M.- Les anti-inflammatoires non stéroïdiens. Rev Med Liège, 1996, 51, 123-125.
2. Scheen AJ.- A propos du mécanisme d'action des anti-inflammatoires. Rev Med Liège, 1996, 51, 610-611.
3. Fitzgerald GA, Patrono C.- The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med, 2001, 345, 433-442.
4. Scheen AJ.- Le rofécoxib (Vioxx®). Rev Med Liège, 2000, 55, 751-753.
5. Scheen AJ.- Le célécoxib (Celebrex®). Rev Med Liège, 2001, 56, 53-55.
6. Scheen AJ, Malaise M.- Valdécoxib (Bextra®). Rev. Med. Liège, 2004, 59, 251-254.
7. Leclercq P. Malaise M.- Etoricoxib (Arcoxia®). Rev. Med. Liège, 2004, 59, 345-349.
8. Mukherjee D, Nissen SE, Topol EJ.- Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001, 286, 954-959.
9. Merck & Co.- Merck announces voluntary worldwide withdrawal of VIOXX®. http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp
10. Reginster JY, Betz R.- Evidence-based medicine. Apport des études épidémiologiques. Rev Med Liège, 2000, 55, 211-215.
11. Mamdani M, Rochan P, Juurlink DN, et al.- Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med, 2003, 163, 481-486.
12. Ray WA, Stein CM, Daugherty JR, et al.- COX-2 selective non-steroidal anti-inflammatory drugs and risks of serious coronary heart disease. Lancet, 2002, 360, 1071-1073.
13. Solomon DH, Schneeweis S, Glynn RJ, et al.- Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation, 2004, 109, 2068-2073.
14. Whelton A, Spalding AM, White WB, et al- Rofecoxib increases cardiovascular events in arthritis patients but celecoxib and non specific nonsteroidal anti-inflammatory drugs do not: results from a large New England health care claims database (abstract). JAAC, 2004, 43 (Suppl A), 838-2.
15. Graham DJ, Campen D, Cheetham C, et al.- Risk of acute cardiac events among patients treated with cyclooxygenase-2 selective and non-selective nonsteroidal antiinflammatory drugs. Pharmacoepidemiol Drug Saf, 2004, 13 (Suppl. 1), S287-S288 (see abstract 571 at www.oroalliance.com/CHARLES/ispe2004. ppt)
16. Scheen AJ.- Evidence-based medicine. Apport des essais cliniques contrôlés. Rev Med Liège, 2000, 55, 216-219.
17. Bombardier C, Laine L, Reicin A, et al. for the VIGOR Study Group.- Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med, 2000, 343, 1520-1528.
18. Komstan MA, Weir MR, Reicin A, et al.- Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation, 2001, 104, 2280-2288.
19. Reicin AS, Shapiro D, Sperling RS, et al.- Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol, 2002, 89, 204-209.
20. Scheen AJ.- A propos du concept de classe pharmacothérapeutique (Editorial). Med Hyg, 2004, 62, 1587-1588.
21. Whelton A, White WB, Bello AE, et al for the SUCCESS-VII Investigators.- Effects of celecoxib and rofecoxib on blood pressure and edema in patients > 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol, 2002, 90, 959-963.
22. White WB et al.- Cardiovascular thromboembolic events in arthritis trials of the cyclooxygenase-2 specific inhibitor celecoxib. Am J Cardiol, 2003, 92, 411-418
23. White WB, Faich G, Whelton A, et al.- Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol, 2002, 89, 425-430.
24. Mamdani M et al.- Cyclooxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet, 2004, 363, 1751-1756.
25. Farkouh ME, Kirshner H, Harrington RA, et al.- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet, 2004, 364, 675-684.
26. Krzesinski JM, Piront P.- Décompensation cardiaque, fonction rénale et anti-inflammatoires non stéroïdiens. Rev Med Liège, 2002, 57, 582-586.
27. Scheen AJ.- Comment j'explore ... Le risque cardiovasculaire absolu à 10 ans: de Framingham 1998 à SCORE 2003. Rev Med Liège, 2004, 59, 460-466.
28. Greenberg HE, Gottesdiener K, Huntington M, et al.- A new cyclo-oxygenase inhibitor, rofecoxib (VIOXX) did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol, 2000, 40, 1509-1515.